The study of interfering of endogenous VEGF-C genes and the protein expression gastric cancer cell with siRNA technique

Journal of Sichuan University (Medical Science)

Volumn 44, Issue 5, 2013, Pages 740-743

  Guo, Mei Mei ^a,b   Wang, Yone ^a,b   Han, Fang Hai ^a,b  

^a GUANGDONG MEDICAL UNIVERSITY   (China)

^b THE FIRST AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

Author keywords

Gastric cancer; Lymph vessel growth factor; SiRNA in vitro

Indexed keywords

SMALL INTERFERING RNA; VASCULOTROPIN C;

ARTICLE; GENETIC TRANSFECTION; GENETICS; HUMAN; PATHOLOGY; RNA INTERFERENCE; STOMACH TUMOR; TUMOR CELL LINE;

CELL LINE, TUMOR; HUMANS; RNA INTERFERENCE; RNA, SMALL INTERFERING; STOMACH NEOPLASMS; TRANSFECTION; VASCULAR ENDOTHELIAL GROWTH FACTOR C;

EID: 84885924592     PISSN: 1672173X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Dixelius J, Makinen T, Wirzenius M, et al. Ligand-induced vascular endothelial growth factor receptor-3 (VEGFR-3) heterodimerization with VEGFR-2 in primary lymphatic endothelial cells regulates tyrosine phosphorylation sites. J Biol Chem, 2003, 278(42), 40973-40979. (Pubitemid 37280919)
2. Joukov V, Pajusola K. Kaipainen A, et al. A novel vascular endothelial growth factor VEGF-C is a ligand for the flt-4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinasese. EMBOJ, 1996, l5(5) : 290-295.
3. Breslin JW, Yuan SY, Wu MH. VEGF-C alters barrier function of cultured lymphatic endothelial cells through a VEGFR-3-dependent mechanism. Lymphat Res Biol, 2007, 5 (2): 105-113. (Pubitemid 47585359)
4. Karpanen M, Egeblad M, Karkkainen MJ, et al. Vascular endothelial growth factor C promotes tumour lymphangiogenesis and intralymphatic tumour growth. Cancer Res, 2001, 16(11):1786-1790. (Pubitemid 32691984)
5. Witzenbichler B, Asahara T, Murohara T, et al. Vascular endothelial growth factor-C (VEGF-C/VEGF-2) promotes angiogenesis in the setting of tissue ischemia. Am J Pathol, 1998:153(2): 381-394. (Pubitemid 28373650)
6. Hirakawa S, Hong YK, Harvey N, et al. Identification of vascular lineage-specific genes by transcriptional profiling of isolated blood vascular and lymphatic endothelial cells. Am J Pathol, 2003, 162(2) : 575-586. (Pubitemid 36267864)
7. Duff SE, Li C. Renehan AO. et al. Immunodetection and molecular forms of plasma vascular endothelial growth factorC. Int J Oncol, 2003(22(2): 339-343.
8. Beasley NJ, Prevo R, Banerji S, et al. Intratumoral lymphangiogenesis and lymph node metastasis in head and neck cancer. Cancer Res, 2002, 62(5), 1315-1320. (Pubitemid 34407785)
9. Ishikawa M, Kitayama J, Kazama S, et al. Expression of vascular endothelial growth factor (VEGF)-C in preoperative biopsy specimens and metastatic foci of regional lymph nodes in submucosal gastric carcinoma. World J Surg Oncol, 200513 (1): 1172-1179.
10. Tanaka K, Nishioka J, Kato K, et al. Mitotic checkpoint protein hsMAD2 as a marker predicting liver metastasis of human gastric cancers. Jpn J Cancer Res, 2001, 92(9), 952-958.
11. Bikfalvil A, Moenner M, Javerzat S, et al. Inhibition of angiogenesis and the angiogenesis/invasion shift. Biochem Soc Trans, 2011, 39(6): 89-93.
12. Ferrara N, Henzel WJ. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun, 1989, 161(2), 851-858. (Pubitemid 19162712)
13. Helfrich I, Scheffrahn I, Bartling S, et al. Resistance to antiangiogenic therapy is directed by vascular phenotype, vessel stabilization, and maturation in malignant melanoma. J Exp Med, 2010, 207(3): 491-503.
14. Wagner AD, Arnold D, Grothey AA, et al. Anti-angiogenic therapies for metastatic colorectal cancer. J Cancer Res, 2009, 87(9), 95-99.
15. Saranadasa M, Wang ES. Vascular endothelial growth factor inhibition¡conflicting roles in tumor growth. Cytokine, 2011, 53(2) :115-129.
16. Keunen O, Johansson M, Oudin A, et al. Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma. Proc Natl Acad Sei USA, 2011, 108 (5): 3749-3754.
17. Torben FH, Anders J. Clinical implications of genetic variations in the VEGF system in relation to colorectal cancer. Pharmacogenomics, 2011, 12(12), 1681-1693.
18. Baluk P, Hashizume H, McDonald DM. Cellular abnormalities of blood vessels as targets in cancer. Curr Opin Genet Dev, 2005, 15(3): 102-111. (Pubitemid 40127638)